Cantabio Pharmaceuticals Inc
OTC:CTBO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cantabio Pharmaceuticals Inc
OTC:CTBO
|
US |
|
Block Inc
F:SQ3
|
US |
Cantabio Pharmaceuticals Inc
Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company, which engages in the commercialization of novel therapies and the intellectual property generated from the research and development activities for Parkinson's, Alzheimer's diseases, and any other related diseases. The company is headquartered in Palo Alto, California. The company went IPO on 2013-11-20. The firm is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. The Company’s small molecule therapy candidates program (CB101) and protein therapy candidate (CB201) targets Parkinson’s disease and a range of neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease and stroke. The company also has two additional small molecule pharmacological chaperone programs for the treatment of Alzheimer’s Disease (and other related dementias); CB301, targeting the Tau protein, for the development of Alzheimer’s therapeutics, and CB401, targeting the Aß peptide in Alzheimer’s drug research. The Company’s strategy integrates therapeutic focus on targeting family biophysics and drug discovery technology.
Cantabio Pharmaceuticals, Inc. is a preclinical stage biotechnology company, which engages in the commercialization of novel therapies and the intellectual property generated from the research and development activities for Parkinson's, Alzheimer's diseases, and any other related diseases. The company is headquartered in Palo Alto, California. The company went IPO on 2013-11-20. The firm is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. The Company’s small molecule therapy candidates program (CB101) and protein therapy candidate (CB201) targets Parkinson’s disease and a range of neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease and stroke. The company also has two additional small molecule pharmacological chaperone programs for the treatment of Alzheimer’s Disease (and other related dementias); CB301, targeting the Tau protein, for the development of Alzheimer’s therapeutics, and CB401, targeting the Aß peptide in Alzheimer’s drug research. The Company’s strategy integrates therapeutic focus on targeting family biophysics and drug discovery technology.
